JP2010516626A5 - - Google Patents

Download PDF

Info

Publication number
JP2010516626A5
JP2010516626A5 JP2009545734A JP2009545734A JP2010516626A5 JP 2010516626 A5 JP2010516626 A5 JP 2010516626A5 JP 2009545734 A JP2009545734 A JP 2009545734A JP 2009545734 A JP2009545734 A JP 2009545734A JP 2010516626 A5 JP2010516626 A5 JP 2010516626A5
Authority
JP
Japan
Prior art keywords
cancer
cyclodextrin
pharmaceutical composition
composition according
iodo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009545734A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010516626A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/051214 external-priority patent/WO2008089272A1/en
Publication of JP2010516626A publication Critical patent/JP2010516626A/ja
Publication of JP2010516626A5 publication Critical patent/JP2010516626A5/ja
Withdrawn legal-status Critical Current

Links

JP2009545734A 2007-01-16 2008-01-16 ガン治療剤 Withdrawn JP2010516626A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88075507P 2007-01-16 2007-01-16
PCT/US2008/051214 WO2008089272A1 (en) 2007-01-16 2008-01-16 Formulations for cancer treatment

Publications (2)

Publication Number Publication Date
JP2010516626A JP2010516626A (ja) 2010-05-20
JP2010516626A5 true JP2010516626A5 (https=) 2011-03-03

Family

ID=39350967

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009545734A Withdrawn JP2010516626A (ja) 2007-01-16 2008-01-16 ガン治療剤

Country Status (32)

Country Link
US (1) US20080176946A1 (https=)
EP (2) EP2476461A3 (https=)
JP (1) JP2010516626A (https=)
KR (1) KR20090113852A (https=)
CN (1) CN101668561A (https=)
AU (1) AU2008206294A1 (https=)
BR (1) BRPI0806590A2 (https=)
CA (1) CA2674600A1 (https=)
CO (1) CO6220840A2 (https=)
CR (1) CR10975A (https=)
CY (1) CY1113819T1 (https=)
DK (1) DK2121139T3 (https=)
DO (1) DOP2009000178A (https=)
EC (1) ECSP099577A (https=)
ES (1) ES2395690T3 (https=)
GB (1) GB2447796C (https=)
GT (1) GT200900201A (https=)
HR (1) HRP20120960T1 (https=)
IL (1) IL199682A0 (https=)
MA (1) MA34559B1 (https=)
MX (1) MX2009007596A (https=)
NZ (1) NZ579098A (https=)
PL (1) PL2121139T3 (https=)
PT (1) PT2121139E (https=)
RS (1) RS52633B (https=)
RU (2) RU2481830C2 (https=)
SG (1) SG178714A1 (https=)
SI (1) SI2121139T1 (https=)
SV (1) SV2009003335A (https=)
TN (1) TN2009000292A1 (https=)
UA (1) UA100852C2 (https=)
WO (1) WO2008089272A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7961081B2 (en) * 2003-05-22 2011-06-14 John Tomlienovic Anti-theft system and method
CA2612979A1 (en) * 2005-06-10 2006-12-21 Bipar Sciences, Inc. Parp modulators and treatment of cancer
CA2615374A1 (en) 2005-07-18 2007-01-25 Ernest Kun Kun Treatment of cancer
WO2008147418A1 (en) * 2006-06-12 2008-12-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20100160442A1 (en) * 2006-07-18 2010-06-24 Ossovskaya Valeria S Formulations for cancer treatment
JP2010502730A (ja) 2006-09-05 2010-01-28 バイパー サイエンシズ,インコーポレイティド 癌の治療法
CA2662337A1 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof
US7538252B2 (en) * 2006-09-05 2009-05-26 Bipar Sciences, Inc. Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
WO2009051815A1 (en) * 2007-10-19 2009-04-23 Bipar Sciences, Inc. Methods and compositions for the treatment of cancer using benzopyrone-type parp inhibitors
CN103169973A (zh) 2007-11-12 2013-06-26 彼帕科学公司 使用4-碘-3-硝基苯甲酰胺化合物与抗肿瘤剂组合治疗乳腺癌
CA2713156A1 (en) * 2008-02-04 2009-08-13 Bipar Sciences, Inc. Methods of diagnosing and treating parp-mediated diseases
US8026271B2 (en) * 2008-07-11 2011-09-27 National Health Research Institutes Formulations of indol-3-yl-2-oxoacetamide compounds
WO2010036226A1 (en) * 2008-09-26 2010-04-01 George Nelson Process for treatment of rheumatoid arthritis, tremors/parkinson's disease and multiple sclerosis
MX2011003277A (es) * 2008-10-14 2012-09-21 Salubrious Pharmaceuticals LLC Proceso para el tratamiento de la artritis reumatoide, temblores/enfermedad de parkinson, esclerosis multiple y cancer de tipo no viral.
US20140051737A1 (en) * 2011-05-10 2014-02-20 Universite Laval Methods for the treatment and diagnostic of pulmonary arterial hypertension
AU2013352369B2 (en) * 2012-11-30 2016-07-28 Novartis Ag. Novel pharmaceutical composition
WO2017192618A1 (en) * 2016-05-02 2017-11-09 Symbios Technologies, Inc. Electrochemical plasma activated aqueous chemotherapeutics
US11433074B2 (en) 2017-06-22 2022-09-06 Triact Therapeutics, Inc. Methods of treating glioblastoma
KR20250016494A (ko) 2017-09-26 2025-02-03 테사로, 인코포레이티드 니라파립 제제
US11628144B2 (en) 2017-09-29 2023-04-18 Triact Therapeutics, Inc. Iniparib formulations and uses thereof
WO2020246737A1 (ko) * 2019-06-04 2020-12-10 사회복지법인 삼성생명공익재단 콰시노이드를 포함하는 거세 저항성 전립선암 치료용 조성물
CZ309587B6 (cs) * 2021-01-22 2023-05-03 Oncora S.R.O. Mikroemulzní prekoncentrát s obsahem kladribinu a způsob jeho přípravy
GB2611315B (en) * 2021-09-29 2024-01-03 Siemens Healthcare Gmbh Method of operating a magnetic resonance scanner
EP4537108A1 (en) * 2022-06-10 2025-04-16 Dana-Farber Cancer Institute, Inc. Allelic imbalance of chromatin accessibility in cancer identifies causal risk variants and their mechanisms

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0348655A (ja) * 1989-07-14 1991-03-01 Shionogi & Co Ltd プロスタグランジンd↓2類の安定化
US5633282A (en) * 1990-05-25 1997-05-27 British Technology Group Limited Inhibition of viral infection
US5232735A (en) * 1990-06-01 1993-08-03 Bioresearch, Inc. Ingestibles containing substantially tasteless sweetness inhibitors as bitter taste reducers or substantially tasteless bitter inhibitors as sweet taste reducers
US5637618A (en) * 1990-06-01 1997-06-10 Bioresearch, Inc. Specific eatable taste modifiers
US5631038A (en) * 1990-06-01 1997-05-20 Bioresearch, Inc. Specific eatable taste modifiers
US5484951A (en) * 1990-10-19 1996-01-16 Octamer, Incorporated 5-iodo-6-amino-6-nitroso-1,2-benzopyrones useful as cytostatic and antiviral agents
US5464871A (en) 1993-05-12 1995-11-07 Octamer, Inc. Aromatic nitro and nitroso compounds and their metabolites useful as anti-viral and anti-tumor agents
US5877185A (en) * 1991-10-22 1999-03-02 Octamer, Inc. Synergistic compositions useful as anti-tumor agents
US5516941A (en) * 1991-10-22 1996-05-14 Octamer, Inc. Specific inactivators of "retroviral" (asymmetric) zinc fingers
US5482975A (en) * 1991-10-22 1996-01-09 Octamer, Inc. Adenosine diphosphoribose polymerase binding nitroso aromatic compounds useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents
US5652260A (en) * 1991-10-22 1997-07-29 Octamer, Inc. Adenosine diphosphoribose polymerase binding nitroso aromatic compound useful as retroviral inactivating agents, anti-retroviral agents and anti-tumor agents
GB9200247D0 (en) * 1992-01-07 1992-02-26 Erba Carlo Spa Pharmaceutical compositions containing polymer derivative-bound anthracycline glycosides and a method for their preparation
US5558855A (en) 1993-01-25 1996-09-24 Sonus Pharmaceuticals Phase shift colloids as ultrasound contrast agents
US6015792A (en) * 1993-05-26 2000-01-18 Bioresearch, Inc. Specific eatable taste modifiers
US6008250A (en) * 1993-05-26 1999-12-28 Bioresearch, Inc. Specific eatable taste modifiers
US5589483A (en) * 1994-12-21 1996-12-31 Geron Corporation Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence
WO1996038175A1 (en) * 1995-06-02 1996-12-05 Takeda Chemical Industries, Ltd. Stabilized composition comprising an antiulcerative benzimidazole
US5837729A (en) * 1996-04-26 1998-11-17 Metatron, Inc. Methods for treating and preventing HIV infection using acetaminophen and derivatives thereof
WO1998045253A1 (en) * 1997-04-10 1998-10-15 Isotechnika, Inc. Activated iododerivatives for the treatment of cancer and aids
US5908861A (en) * 1997-05-13 1999-06-01 Octamer, Inc. Methods for treating inflammation and inflammatory disease using pADPRT inhibitors
US6696426B2 (en) * 2000-08-22 2004-02-24 Pharmacia Corporation Preservative free ophthalmic oxazolidinone antibiotic drug delivery systems
EP1348432A4 (en) * 2001-01-04 2005-08-10 Daiichi Seiyaku Co CYCLODEXTRIN-CONTAINING PHARMACEUTICAL COMPOSITION
US20050113283A1 (en) * 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor
JP2003321364A (ja) * 2002-05-07 2003-11-11 Eisai Co Ltd シクロデキストリンにより可溶化及び安定化された抗腫瘍剤含有組成物
UA83816C2 (ru) * 2003-01-14 2008-08-26 Тева Фармасьютикал Индастриз, Лтд ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, КОТОРАЯ СОДЕРЖИТ ПЕПТИД И ЗАМЕЩЕННЫЙ β-ЦИКЛОДЕКСТРИН, ДЛЯ ЛЕЧЕНИЯ СИСТЕМНОЙ КРАСНОЙ ВОЛЧАНКИ
WO2005023765A1 (en) * 2003-09-11 2005-03-17 Pharmacia & Upjohn Company Llc Method for catalyzing amidation reactions by the presence of co2
CA2612979A1 (en) * 2005-06-10 2006-12-21 Bipar Sciences, Inc. Parp modulators and treatment of cancer
CA2615374A1 (en) * 2005-07-18 2007-01-25 Ernest Kun Kun Treatment of cancer
WO2008147418A1 (en) * 2006-06-12 2008-12-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
AU2007292302A1 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Methods for designing PARP inhibitors and uses thereof
US7538252B2 (en) * 2006-09-05 2009-05-26 Bipar Sciences, Inc. Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
CA2662337A1 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof
JP2010502730A (ja) * 2006-09-05 2010-01-28 バイパー サイエンシズ,インコーポレイティド 癌の治療法

Similar Documents

Publication Publication Date Title
JP2010516626A5 (https=)
RU2481830C2 (ru) Лекарственные препараты для лечения рака
JP2013522292A5 (https=)
JP2016040288A5 (https=)
JP2013510860A5 (https=)
JP2013545812A5 (https=)
JP2018510139A5 (https=)
JP2013534535A5 (https=)
JP2014012726A5 (https=)
JP2017517538A5 (https=)
BRPI0918010B8 (pt) conector para recipiente descartável para ser usado em máquinas de diálise
JP2010514797A5 (https=)
JP2008525530A5 (https=)
RU2015154275A (ru) Комбинации антитела против pd-l1 и ингибитора mek и/или ингибитора braf
JP2013507415A5 (https=)
JP2009534457A5 (https=)
RU2016122731A (ru) Функционализированные и замещенные индолы в качестве противораковых агентов
JP2016501838A5 (https=)
JP2013502441A5 (https=)
DOP2011000405A (es) Acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil](2-metil-2h-tetrazol-5-il)amino]-2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il]metil]-ciclohexancarboxilico
JP2015524414A5 (https=)
JP2010209101A5 (https=)
JP2020506884A5 (https=)
JP2013544892A5 (https=)
JP2009503110A5 (https=)